Intestinal Research

Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis: Suprabhat Giri, Dhiraj Agrawal, Shivaraj Afzalpurkar, Sunil Kasturi, Amrit Gopan, Sridhar Sundaram, Aditya Kale; Received July 19, 2022 Accepted August 30, 2022; DOI: https://doi.org/10.5217/ir.2022.00094 [Epub ahead of print]; PDF

Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study: Eun Hye Oh, Ye-Jee Kim, Minju Kim, Seung Ha Park, Tae Oh Kim, Sang Hyoung Park; Received July 17, 2022 Accepted August 25, 2022; DOI: https://doi.org/10.5217/ir.2022.00092 [Epub ahead of print]; PDF

Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India: Arshdeep Singh, Vandana Midha, Vikram Narang, Saurabh Kedia, Ramit Mahajan, Pavan Dhoble, Bhavjeet Kaur Kahlon, Ashvin Singh Dhaliwal, Ashish Tripathi, Shivam Kalra, Narender Pal Jain, Namita Bansal, Rupa Banerjee, Devendra Desai, Usha Dutta, Vineet Ahuja, Ajit Sood; Received July 9, 2022 Accepted September 19, 2022; DOI: https://doi.org/10.5217/ir.2022.00087 [Epub ahead of print]; PDF

Laparoscopic surgery contributes to a decrease in short-term complications in surgical ulcerative colitis patients during 2008–2017: a multicenter retrospective study in China: Zerong Cai, Xiaosheng He, Jianfeng Gong, Peng Du, Wenjian Meng, Wei Zhou, Jinbo Jiang, Bin Wu, Weitang Yuan, Qi Xue, Lianwen Yuan, Jinhai Wang, Jiandong Tai, Jie Liang, Weiming Zhu, Ping Lan, Xiaojian Wu; Received January 21, 2022 Accepted April 1, 2022; DOI: https://doi.org/10.5217/ir.2022.00012 [Epub ahead of print]; PDF

Anti-inflammatory properties of butyrate-producing atypical Escherichia coli in a murine colitis model: Ji Hyung Kim, Jee In Yoo, Hyun Woo Ma, I Seul Park, Mijeong Son, Yoojin Shin, Ki Beom Kim, Seung Won Kim, Si Jae Park, Jihye Park; Received September 6, 2022 Accepted September 22, 2022; DOI: https://doi.org/10.5217/ir.2022.00112 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

The role and prospect of tofacitinib in patients with ulcerative colitis: Jun Lee; Received July 26, 2022 Accepted August 27, 2022; DOI: https://doi.org/10.5217/ir.2022.00098 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF

Improvement of ulcerative colitis control by searching and restricting of inflammatory trigger factors in daily clinical practice: Kun-Yu Tsai, Jeng-Fu You, Tzong-Yun Tsai, Yih Jong Chern, Yu-Jen Hsu, Shu-Huan Huang, Wen-Sy Tsai; Received August 3, 2021 Accepted November 16, 2021; DOI: https://doi.org/10.5217/ir.2021.00110 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF

Inflammatory bowel disease (IBD)-disk accurately predicts the daily life burden and parallels disease activity in patients with IBD: Arshdeep Singh, Yogesh Kumar Gupta, Ashvin Singh Dhaliwal, Bhavjeet Kaur Kahlon, Vasu Bansal, Ramit Mahajan, Varun Mehta, Dharmatma Singh, Ramandeep Kaur, Namita Bansal, Vandana Midha, Ajit Sood; Received March 23, 2022 Accepted June 29, 2022; DOI: https://doi.org/10.5217/ir.2022.00037 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease: Seong-Joon Koh, Sung Noh Hong, Soo-Kyung Park, Byong Duk Ye, Kyeong Ok Kim, Jeong Eun Shin, Yong Sik Yoon, Hong Sub Lee, Sung Hoon Jung, Miyoung Choi, Soo-Young Na, Chang Hwan Choi, Joo Sung Kim, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases; Received February 21, 2022 Accepted April 18, 2022; DOI: https://doi.org/10.5217/ir.2022.00029 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF

Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease: Yu Kyung Jun, Hyuk Yoon, Seong-Joon Koh, A Hyeon Kim, Kwang Woo Kim, Jun Won Park, Hyun Jung Lee, Hyoun Woo Kang, Jong Pil Im, Young Soo Park, Joo Sung Kim, on behalf of Seoul National University Inflammatory Bowel Disease Research Network (SIRN); Received April 22, 2022 Accepted June 10, 2022; DOI: https://doi.org/10.5217/ir.2022.00057 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Proposal of novel staging system CNM (Crohn’s primary site, nodes, mesentery) to predict postoperative recurrence of Crohn’s disease: Guduru Venkat Rao, Partha Pal, Anuradha Sekaran, Pradeep Rebala, Manu Tandan, D. Nageshwar Reddy; Received April 1, 2022 Accepted June 6, 2022; DOI: https://doi.org/10.5217/ir.2022.00045 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF

Clinical spectrum of elderly-onset inflammatory bowel disease in India: Yogesh Kumar Gupta, Arshdeep Singh, Vikram Narang, Vandana Midha, Ramit Mahajan, Varun Mehta, Dharmatma Singh, Namita Bansal, Madeline Vithya Barnaba Durairaj, Amit Kumar Dutta, Ajit Sood; Received December 27, 2021 Accepted May 17, 2022; DOI: https://doi.org/10.5217/ir.2021.00177 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF

Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis: Kensuke Sakurai, Takehiko Katsurada, Mutsumi Nishida, Satomi Omotehara, Shinya Fukushima, Shinsuke Otagiri, Kazunori Nagashima, Reizo Onishi, Ryo Takagi, Yoshito Komatsu, Naoya Sakamoto; Received December 3, 2021 Accepted June 6, 2022; DOI: https://doi.org/10.5217/ir.2021.00166 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study: Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye, on behalf of the Korean Association for the Study of Intestinal Diseases; Received December 23, 2021 Accepted February 14, 2022; DOI: https://doi.org/10.5217/ir.2021.00173 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF

Reviewing not Homer’s Iliad, but “Kai Bao Ben Cao”: indigo dye—the past, present, and future: Yusuke Yoshimatsu, Tomohisa Sujino, Takanori Kanai; Received February 7, 2022 Accepted April 23, 2022; DOI: https://doi.org/10.5217/ir.2022.00018 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF

Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease: Seung Yong Shin, Young Kim, Won-Seok Kim, Jung Min Moon, Kang-Moon Lee, Sung-Ae Jung, Hyesook Park, Eun Young Huh, Byung Chang Kim, Soo Chan Lee, Chang Hwan Choi, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases; Received December 10, 2021 Accepted March 10, 2022; DOI: https://doi.org/10.5217/ir.2021.00168 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Interferon-gamma release assay has poor diagnostic accuracy in differentiating intestinal tuberculosis from Crohn’s disease in tuberculosis endemic areas: Karan Sachdeva, Peeyush Kumar, Bhaskar Kante, Sudheer K. Vuyyuru, Srikant Mohta, Mukesh K. Ranjan, Mukesh K. Singh, Mahak Verma, Govind Makharia, Saurabh Kedia, Vineet Ahuja; Received January 18, 2022 Accepted March 27, 2022; DOI: https://doi.org/10.5217/ir.2022.00010 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF

Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis: Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim, On behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases; Received January 16, 2021 Accepted March 7, 2022; DOI: https://doi.org/10.5217/ir.2022.00007 [Epub ahead of print]
Cited By 2; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

An Asian perspective on irritable bowel syndrome: Kee Wook Jung, Seung-Jae Myung; Received October 5, 2021 Accepted January 16, 2022; DOI: https://doi.org/10.5217/ir.2021.00136 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF

The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis: Jae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, John R Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R Moschen, Neeraj Narula, Grazyna Rydzewska, Axel U Dignass, Simon PL Travis; Received January 10, 2022 Accepted March 16, 2022; DOI: https://doi.org/10.5217/ir.2022.00006 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis: Katsuyoshi Matsuoka, Kanae Togo, Noritoshi Yoshii, Masato Hoshi, Shoko Arai; Received November 3, 2021 Accepted January 17, 2022; DOI: https://doi.org/10.5217/ir.2021.00154 [Epub ahead of print]
Cited By 1; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial: Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Katsuyoshi Matsuoka, Masayuki Saruta, Taku Kobayashi, Brian G Feagan, Chantal Tasset, Robin Besuyen, Chohee Yun, Gerald Crans, Jie Zhang, Akira Kondo, Mamoru Watanabe; Received October 21, 2021 Accepted December 31, 2021; DOI: https://doi.org/10.5217/ir.2021.00143 [Epub ahead of print]
Cited By 2; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Ahead-of Print